Drug Trial Radar · NCT07802652
Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Feb 1, 2027
Primary completion
Nov 1, 2031
Study completion Nov 1, 2031
Sponsor
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AGENCE NATIONALE DE RECHERCHE
- First posted
- Sep 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this randomized phase II trial is to assess, independently in advanced/metastatic UPS and DDLPS, the antitumor activity of DT-7012 combined with doxorubicin as first-line systemic therapy.
Conditions
- Undifferentiated Pleomorphic Sarcoma (UPS)
- Dedifferentiated Liposarcoma (DDLPS)
Interventions
DT-7012Drug
DT-7012 administered IV at 10 mg/kg on Day 1 of each 21-day cycle for a total maximum of 24 months
DoxorubicinDrug
Doxorubicin administered IV at 75 mg/m2 on Day 1 of each 21-day cycle, up to 6 cycles or according to cumulative dose limits and local standards
Primary outcomes
What the sponsor says the trial is designed to measure.
- 6-month progression-free rate (PFR6)Time frame: from the enrollment to 24 weeks after treatment onset
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gustave Roussy
Villejuif, Val de Marne, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.